In a phase 1b–2 study, a five-agent treatment aimed at tumor survival pathways in relapsed and refractory diffuse large B-cell lymphoma was associated with a complete response in 38% of the patients.
The New England Journal of Medicine: Search Results in Hematology/Oncology
